Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : STLW -- Ignore unavailable to you. Want to Upgrade?

To: Secret_Agent_Man who wrote (32)	7/22/2000 10:43:03 PM
From: kcmike	Respond to of 75

I knew there was a reason. Thanks for the clarification! I would probably buy some METHA options if they went out past JAN, but I am not that confident that the deal will be done by then. That will probably be cutting it close. Even if I do buy METHA, I have the same desire ... I hope STLW soars!

To: Secret_Agent_Man who wrote (32)	7/23/2000 5:47:31 PM
From: mor2danc	Read Replies (1) \| Respond to of 75

STLW, they have offered investors a great payback, I have been watching it for a couple weeks, WOW, CONGRATS TO ALL. A rocket soon to be is AVAX Technologies, Inc. it will be on POWERLUNCH on Monday by popular request, I suggest you watch for it. (FLOAT: 10.6 million shares) AVXT: the facts! (updated: 4:11 PM 07/21/2000) -The cancer vaccine has 55% success ratio (compared to 22% with the current best known gold standard treatment). -Nine years of data; and all data was reported, nothing was deleted or held back. -The vaccine is virtually non toxic. -Commercialized and selling cancer vaccine to patients in Australia, and patients will travel. -Plans are in process to open up business soon in Netherlands. -Plans are in process to open up business soon in Germany. -Plans are in the works on doing business in Japan. -Launch of MVAX in New Zealand planned soon! -Very close to patent approval for the other 3 cancer fighting compounds. -Patent filings for the topoismerase inhibitor and cancer fighting anti-estrogen compounds expected. -The company is planning a move to the national market on NASDAQ this year. -M-VAX blows away the current gold standard melanoma treatment, no contest. -AVAX To Acquire All Patent Rights from the Cell and Gene Therapy Laboratory of Dr. David Klatzmann at UPMC Genopoietic to Become Wholly Owned Subsidiary of AVAX Technologies. -PIPELINE: add the great AVXT pipeline to that of Genopoietics: that should make AVXT the global leader in the personalized treatment field (13 products). 1:Cartilage repair ,2:joint repair, 3:bone marrow transplants, 4:auto immune deseases, 5:multiple sclerosis, 6:gene therapy for cancer, 7:organ transplants, 8:anticancer topoisomerase inhibitor compounds, 9:cancer fighting anti-estrogen compounds, 10:M-VAX for melonoma, 11:O-VAX for ovarian cancer, 12:L-VAX for leukemia, 13:B-VAX for breast cancer. (only a 180 million dollar MARKET CAP). -CEO said in interview that he expects news on patent approvals for his 2 other cancer drugs. -AVXT recently got 25 million dollars in a private placement so money is not a current issue. -Expect to hear more on M-VAX sales; expect to hear more on O-VAX , B-VAX and L-VAX. -M-Vax is in late stage trial. -O-Vax is early stage and other indications are in preclinical. -Expect to hear a few more cancer applications for our vaccine (other types of cancer). -Genopoietic deal will be finalized in a matter of a few weeks: 07/19/2000. -SMALL MARKET CAP, HUGE PIPELINE (go ahead and compare it to others!). -Dr. Jonas spoke briefly of a retro virus that Genpoietic was working on but didnt elaborate further. Hmmm. -AVAX CEO stated they are looking aggessively into the possibility of doing the vaccine for earlier stage patients too. -The company stated there has been no regulatory inquiries or compliance concerns, zero. -Start of clinical development of topoisomerase inhibitors planned for later this year. -Start of clinical development in one additional cancer indication planned this year. -Extension of MVAX to earlier stage patients in progress through low-dose arm in current MM trial. -Extension of MVAX to patients in Stage 4 MM in progress. -Patients who showed a welt at the injection site (a dth response) had an 85% survival rate. ABSOULETY ASTOUNDING! avxtinvestors.homestead.com this wasUPDATED: 07/18/2000 ... Please BOOKMARK and PASS THIS ON, thank you. This is just the ground floor for this company; much more to come, here's the history of press releases: avax-tech.com